Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 113

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 113
---
 defined as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction
to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes
that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing
the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input
that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used
to measure fair value:

<div align='center'>58</div>

Level 1 - Inputs are unadjusted quoted prices
in active markets for identical assets or liabilities.

Level 2 - Inputs are quoted prices for similar
assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through
market corroboration, for substantially the full term of the financial instrument.

Level 3 - Inputs are unobservable inputs based
on our assumptions.

New Accounting Pronouncements

The Company considered the applicability and impact
of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance
sheets or statement of operations and comprehensive loss.

<div align='center'>59

MANAGEMENT</div>

Executive Officers

The following table sets forth certain information regarding our executive
officers and directors as of the date of this prospectus.

| Name                      |     | Age |     | Director Since |     | Position                                        |
| Cuong Do                  |     |  59 |     |           2016 |     | Chief Executive Officer, President and Director |
| Joanne Wendy Kim          |     |  70 |     |             -- |     | Chief Financial Officer                         |
| Joseph M. Palumbo, MD     |     |  65 |     |             -- |     | Chief Medical Officer                           |
| Jim Lang                  |     |  60 |     |           2016 |     | Chairman of the Board                           |
| Amy S. Chappell, MD, FAAN |     |  74 |     |           2025 |     | Director                                        |
| Kameel D. Farag           |     |  47 |     |           2025 |     | Director                                        |
| Sigmund Rogich            |